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Abstract
It has been postulated that the failing heart suffers from chronic energy starvation, and that derangements in cardiac energy conversion are
accessory to the progressive nature of this disease. The molecular mechanisms driving this ‘metabolic remodelling’ process and their
significance for the development of cardiac failure are still open to discussion. Next to changes in mitochondrial function, the hypertrophied
heart is characterized by a marked shift in substrate preference away from fatty acids towards glucose. It has been argued that the decline in
fatty acid oxidation is not fully compensated for by a rise in glucose oxidation, thereby imposing an additional burden on overall ATP
generating capacity. Several lines of evidence suggest that these metabolic adaptations are brought about, at least in part, by alterations in the
rate of transcription of genes encoding for proteins involved in substrate transport and metabolism. Here, the principal metabolic changes are
reviewed and the various molecular mechanisms that are likely to play a role are discussed. In addition, the potential significance of these
changes for the aetiology of heart failure is evaluated.
D 2003 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Heart failure is a major cause of morbidity and mortal-
ity. Patients suffering from hypertension and surviving
myocardial infarction in particular are at risk of developing
cardiac failure. The development of heart failure is asso-
ciated with a plethora of intracellular changes, including
alterations in calcium handling, sarcomere function, extra-
cellular matrix composition, and energy metabolism. Given
the wide diversity of processes that are simultaneously
affected, the establishment of clear cause–effect relation-
ships is extremely cumbersome. Furthermore, often it is
unclear whether the molecular changes taking place are to
be considered adaptive or maladaptive responses. Accord-
ingly, the identification of key processes setting off a
cascade of detrimental cellular changes, ultimately leading
to the development of cardiac failure, is still subject of
intense research. The present review focuses primarily on
alterations in cardiac energy metabolism and their potential
significance for the development of cardiac failure, follow-
ing pressure- or volume-overload, or regional myocardial
infarction.
The majority of experimental and clinical studies indi-
cates that the hypertrophied and failing myocardium is
characterized by changes in energy and substrate metabo-
lism, including alterations in high-energy-phosphate con-
tent, mitochondrial function and an increased dependence
on glucose as substrate. Theoretically, these metabolic
alterations could reflect either an increased energy demand
of the cardiac muscle, or compromised capacity to generate
sufficient amounts of ATP, or a combination of both. Since
mitochondria are the principal sites of ATP regeneration,
limitations in oxygen delivery or intrinsic defects in mito-
chondrial function, may well be responsible for the observed
energetic alterations. The functional significance of the shift
in substrate preference from fatty acids (FA) towards glu-
cose is still enigmatic. Even more so, it is still being debated
whether this metabolic shift should be considered adaptive
or maladaptive.
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 2. The failing heart: an energy compromised organ?
2.1. Alterations in high-energy phosphate metabolism
The continuous resynthesis of ATP via mitochondrial
oxidative phosphorylation is mandatory for the maintenance
of the contractile process. The creatine kinase–phosphocre-
atine (CK–PCr) shuttle ensures delivery of ATP from
mitochondria to the myofibrils. Pre-clinical as well as
clinical studies, employing either biochemical or
31P-NMR
techniques to monitor High-Energy Phosphate (HEP) con-
tent, indicated that energy metabolism is affected during
compensated hypertrophy and cardiac failure, as evidenced
by the decline in cardiac PCr content, whether or not in
combination with a reduction in ATP content [1–3].A sa
consequence, the ratio of PCr/ATP, being an index of energy
reserve, is reduced. Indeed, it was reported that the PCr/ATP
ratio correlated well with the severity of failure and may be
of prognostic value [1]. It is of note that the changes in HEP
content coincide with a diminished total CK activity and/or
change in CK-isoform distribution in the hypertrophied and
failing heart [4]. The reduction in PCr along with a reduced
CK activity will decrease CK flux rate, which in turn may
limit the ability of the failing heart to respond to inotropic
challenges [5].
2.2. Mitochondrial dysfunction
The decline in high-energy phosphates might be indica-
tive for impaired mitochondrial function. Mitochondrial
oxygen consumption rate was substantially reduced in an
experimental model of post-infarction cardiac failure [6].
Similar observations were made in explanted hearts from
patients with ischemic and idiopathic dilated cardiomyopa-
thy [7]. Furthermore, reductions in the tissue content and
activity of complex I through IV of the respiratory chain
have been reported in animal models of cardiac failure and
in end-stage human failing hearts [2,8,9]. It is important to
realize that these observations were all made in failing
hearts. No changes in mitochondrial function were found
in hypertrophic ferret hearts [10]. Furthermore, in mitochon-
dria isolated from volume-overloaded hearts state 3 and
state 4 respiration remained unchanged suggesting that
respiratory chain activity per se is not affected under these
conditions [11]. Collectively, these findings suggest that
abnormalities in mitochondrial oxidative phosphorylation
represent a late, rather than early, phenomenon in the
development of heart failure.
2.3. Shift in cardiac substrate utilization
Under normal conditions, the oxidation of FA and
glucose covers approximately 65% and 30% of cardiac
energy demand, respectively [12]. Pioneering studies of
Geltman et al. [13] by means of positron emission tomog-
raphy (PET) revealed marked spatial heterogeneity in up-
take and depressed deposition of FA in the left ventricle of
patients suffering from congestive cardiomyopathy. The
application of PET or single photon emission computed
tomography (SPECT) in later clinical studies [14–16]
corroborated the more heterogeneous distribution of FA
uptake and decline in FA utilization in various forms of left
ventricular hypertrophic and dilated cardiomyopathy.
Others, however, observed no abnormalities in FA uptake
and utilization [17], or even reported an increase in FA
uptake in failing human hearts [18]. Notwithstanding these
conflicting data, detailed studies of De las Fuentes et al. [19]
revealed a close quantitative relationship between the in-
crease in left ventricular mass and the decline in FA
oxidation rate. The direction of the alterations in glucose
utilization in the human hypertrophied and/or failing heart is
less consistent as decreased [17,18], unchanged [15] and
increased [16,20] cardiac deposition of radiolabelled fluo-
rodeoxyglucose has been reported.
Likewise, autoradiography studies on hypertension-in-
duced cardiac hypertrophy in the rat revealed that the
cardiac uptake of radiolabelled FA analogues was dimin-
ished and the uptake of 2-deoxyglucose was enhanced [21].
Subsequent studies with ex vivo perfused hypertrophic
hearts from rats subjected to pressure overload [22,23],
volume-overload [11,24], or regional myocardial infarction
[25] almost consistently showed that FA oxidation was
markedly depressed and glucose utilization increased. It is
important to realize, however, that under these conditions a
substantial part of the exogenous glucose was converted into
lactate instead of being oxidized [22]. Given the central role
of the pyruvate dehydrogenase complex (PDC) in destining
pyruvate for either mitochondrial oxidation or conversion to
lactate, alterations in PDC activity might be responsible for
the reduced coupling of glycolysis and glucose oxidation.
Collectively, these observations indicate that the hyper-
trophied heart becomes more dependent on glucose as an
energy-providing substrate. It is unknown, however, wheth-
er the rise in (anaerobic) glycolysis is sufficient to compen-
sate for the decline in FA oxidation in terms of ATP
production.
3. Metabolic remodelling: underlying mechanisms
Various biochemical and genomic mechanisms have
been considered to contribute to the alterations in energy
metabolism in the hypertrophied and failing heart (listed in
Table 1). In this section, the evidence in favour or against
these mechanisms is being evaluated.
3.1. Mitochondrial dysfunction due to DNA damage
Mitochondria contain a variable number of copies of
their own DNA, encoding for transfer and ribosomal RNAs
and several proteins of the respiratory chain. The mito-
chondrial DNA (mtDNA) appears to be more prone to
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 damage than nuclear DNA. The mitochondria lack both an
effective DNA repair system and the protection afforded by
histones, but above all mtDNA is in close proximity to the
major source of intracellular reactive oxygen species
(ROS), namely the respiratory chain itself. With ageing,
the number of mutations in the mtDNA rises sharply, in
particular in tissues with high rates of oxidative phosphor-
ylation, among which the cardiac muscle. Several studies
demonstrated an increased frequency of mutations in
mtDNA in failing hearts [8,26]. Accordingly, it was
postulated that an enhanced accumulation of mtDNA
mutations over time contributes to the development of
mitochondrial aberrations and, hence, to the progression
of heart failure. Indeed, maternally inherited mtDNA
mutations cause several genetic syndromes, among which
cardiac failure [27]. Furthermore, in transgenic mice over-
expressing a proofreading-deficient mitochondrial DNA
polymerase (pol g) in a cardiac-specific manner, the
number of mtDNA mutations rapidly increases and the
animals develop cardiomyopathy [28]. These observations
substantiate the notion that mutations in mtDNA lead to
cardiac dysfunction. On the other hand, changes in mito-
chondrial function in failing hearts of transplant patients
have been reported without any evidence of an increase in
mtDNA mutations [9].
Finally, it has been postulated that mitochondrial effi-
ciency, i.e. ATP produced per oxygen atom consumed, is
reduced due to increased activity of mitochondrial uncou-
pling proteins (UCPs), which may partly dissipate the
mitochondrial electrochemical proton gradient that is nor-
mally used to regenerate ATP [29]. However, both
increases [30] and decreases [31] in UCP2 and UCP3
expression were reported in animals with congestive heart
failure and in patients with end-stage heart failure. Fur-
thermore, the exact biological function of UCP2 and UCP3
is far from clear. Rather than mitochondrial uncoupling,
these proteins have been postulated to be involved in the
export of FA out of the mitochondrial matrix and inhibition
of mitochondrial ROS production, implying beneficial
instead of detrimental properties of these UCP isoforms
[32].
3.2. Reactive oxygen species and nitric oxide
The ROS will inflict mitochondrial damage by attacking
mtDNA and mitochondrial proteins, thereby compromising
mitochondrial aerobic capacity. Conversely, dysfunction of
the respiratory chain is believed to be associated with
enhanced ROS production. For instance, genetic ablation
of the cardiac-enriched isoform of the Adenine Nucleotide
Translocase (ANT-1), facilitating the exchange of ATP
against ADP across the mitochondrial inner membrane,
disturbs mitochondrial energy production and increases
mitochondrial ROS production [33]. In addition, extra-
mitochondrial sources of ROS are also worth considering.
The activity of xanthine oxidase, which generates superox-
ide anion during purine catabolism, is enhanced in the
failing heart [34]. The xanthine oxidase inhibitor allopurinol
was found to improve mechano-energetic coupling in pac-
ing-induced heart failure [34,35]. By analogy, it is tempting
to speculate that NADPH oxidase, which is activated during
hypertrophy and failure, affects cardiac energetics as well
[36].
Nitric oxide (NO) has also been implicated as a modu-
lator of mitochondrial respiration as it competes with
oxygen for binding to cytochrome-c oxidase (complex IV)
[37]. Accordingly, the administration of NO generating
reagents to isolated hearts lowers oxygen consumption,
whereas inhibitors of NO synthesis stimulate oxygen con-
sumption [38]. Interestingly, in the hypertrophic myocardi-
um mitochondrial respiration appears to be more sensitive to
inhibition by NO [37,39] and inhibition of NO production
increases myocardial oxygen consumption in pacing-in-
duced heart failure [40].
There is ongoing controversy whether the production of
NO is either depressed or stimulated during cardiac failure.
Various studies documented that expression of inducible
NO synthase (iNOS) is enhanced in the failing heart [41],
thereby suggesting that NO production will be increased.
Conversely, others failed to measure increased NO forma-
tion, or actually observed a decline in NO production in
the failing myocardium (for recent review, see Ref. [42]).
To reconcile these conflicting results, it has been put
forward that inhibition of endothelial NOS (eNOS) activity
is quantitatively more important than the induction of
iNOS under these conditions. As discussed later, NO
production has also been linked to changes in substrate
utilization.
Table 1
Putative mechanisms underlying energetic alterations during cardiac
hypertrophy and failure
Reduced/impaired mitochondrial activity:
–Limitations in O2 supply
–Increased NO production
a
–Enhanced UCP activity
–ROS-induced mitochondrial DNA damage
Increased glycolysis:
–Reduced FA metabolism (Randle cycle)
–Limitations in O2 supply
–Activation of AMPK
–Reduced NO production
a
–Transcriptional upregulation (HIF-mediated)
Reduced FA oxidation:
–Increased glucose metabolism (Randle cycle)
–Limitations in O2 supply
–Impaired trans-sarcolemmal transport
–Loss of carnitine
–Reduced mitochondrial activity
–Transcriptional downregulation (via reduction PPAR activity)
a As discussed in text, it is still being debated whether nitric oxide (NO)
synthesis is increased or decreased during cardiac hypertrophy and failure.
UCP—uncoupling protein; ROS—reactive oxygen species; AMPK—
AMP-activated protein kinase; HIF—hypoxia-inducible factor; PPAR—
peroxisome proliferator-activated receptor.
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 3.3. Mismatch between oxygen supply and demand?
The drop in PCr/ATP ratio as well as the shift in substrate
preference towards glucose are compatible with the notion
of a mismatch between oxygen supply and demand in the
failing heart. Although cardiac hypertrophy secondary to
hypertension is associated with a reduced capillary density
and, thus, an increase in the diffusion distance from capil-
lary to mitochondrion, it is questionable whether the oxygen
diffusion becomes limiting. In patients with idiopathic
dilated cardiomyopathy myocardial blood flow at rest is
similar to that of healthy controls, but dipyridamole infusion
revealed that blood flow reserve is markedly reduced in
these patients [43]. In other studies, however, oxygen supply
seemed to match oxygen needs, even when workload was
increased by dobutamine or exercise [44,45]. Imaging
techniques that allow estimation of the ratio of deoxygen-
ated/oxygenated myoglobin failed to detect derangements in
intracellular oxygen availability in pressure overload hyper-
trophy [44], pacing-induced heart failure [45] and post-
infarction failure [46]. These observations suggest that
demand ischemia is of limited importance in the aetiology
of cardiac failure and, by inference, that oxygen shortage is
not the primary trigger for the shift in substrate preference
towards glucose.
3.4. Enhanced glycolysis and hypoxia-inducible factor
The mechanism underlying the enhancement of glycol-
ysis in the hypertrophied and failing heart is incompletely
understood. Early findings that the activity and isoform
distribution of a number of glycolytic enzymes (hexoki-
nase, lactate dehydrogenase) were changed in the hyper-
trophied myocardium indicated that alterations in glucose
metabolism might be related to changes in gene expression
[47]. Subsequent studies showed that hypertrophy and
failure are associated with a diminished expression of the
insulin-dependent glucose transporter (GLUT4) and un-
changed or increased expression of GLUT1 [48–50].
Interestingly, the expression of the monocarboxylate trans-
porter-1 (MCT1), facilitating the sarcolemmal transport of
lactate and pyruvate, increased substantially during heart
failure [51].
In a rat model of monocrotaline-induced right ventricular
pressure overload, immunohistochemical analysis revealed
induction of the transcription factor hypoxia-inducible fac-
tor-1a (HIF-1a) [52]. The HIF-1a/HIF-1h dimer binds to
the consensus DNA sequence (C/G/T)ACGTGC(G/T), pres-
ent in the promoter regions of GLUT1 and the glycolytic
enzymes aldolase (A-type), phosphoglycerate kinase (PGK),
a-enolase (ENO1), and LDH-A [53,54]. In this respect, the
enhanced expression of GLUT1 and LDH-A [55] is consis-
tent with the idea that HIF-mediated transcriptional activa-
tion accounts for the increased reliance on glycolysis of the
diseased myocardium. To date, however, the contribution of
HIF-mediated transcription in enhancing glycolysis in the
hypertrophic and failing heart is still questionable. As
discussed above, oxygen shortage does not appear to be a
common feature of cardiac hypertrophy and failure. More
importantly, a large number of studies failed to observe
increases or even reported decreases in the mRNA or
protein content or enzyme activity (Vmax) of glucose trans-
porters and glycolytic enzymes both in animal models of
hypertrophy [56–58] and in the failing human heart [2,31].
These observations suggest that the increase in glycolysis is
brought about via post-translational, rather than transcrip-
tional mechanisms.
3.5. AMP-activated protein kinase
In view of the changes in high-energy phosphate metab-
olism, it is conceivable that activation of AMPK, due to the
rise in AMP/ATP ratio, is involved in the shift towards
glucose utilization during cardiac hypertrophy and failure.
Activation of AMPK with the AMP-analogue AICAR leads
to the translocation of GLUT4 from intracellular stores to
the sarcolemma [59]. The observation that patients with
mutations in one of the AMPK subunits and mice over-
expressing this activating AMPK mutant form suffer from
pathological cardiac glycogen accumulation, underscores
the importance of AMPK in cardiac carbohydrate homeo-
stasis [60]. Furthermore, the AMPK-dependent phosphory-
lation of the enzyme 6-phosphofructo-2-kinase also
stimulates glycolysis [61]. Indeed, cardiac hypertrophy
was associated with a marked increase in AMPK activity
and enhanced uptake of 2-deoxyglucose [62].
It is important to realize, however, that AMPK also
activates FA uptake by stimulating the translocation of Fatty
Acid Translocase (FAT/CD36) to the sarcolemma [63].
Furthermore, AMPK phosphorylates acetyl-CoA carboxyl-
ase (ACC), thereby inhibiting the conversion of acetyl-CoA
into malonyl-CoA [64]. As malonyl-CoA is a potent allo-
steric inhibitor of carnitine palmitoyltransferase-1 (CPT1),
the AMPK-mediated inhibition of ACC activity will pro-
mote FA utilization. Accordingly, the fact that activation of
AMPK stimulates the uptake and metabolism of both
glucose and FA is difficult to reconcile with a change in
substrate preference to glucose in the hypertrophied and
failing heart.
3.6. Nitric oxide and glucose utilization
Interestingly, there appears to be an, as yet poorly
understood, relation between NO production and glucose
utilization. Pharmacological inhibition of NO synthesis is
associated with an increase in cardiac glucose utilization
[42,65]. The enhanced uptake of glucose by ex vivo-
perfused hearts from eNOS knockout mice corroborates this
notion [66]. The observation that administration of cGMP
analogues or NO-donors depressed cardiac glucose uptake
by hearts from eNOS knock-out mice suggests that the
effect of NO is cGMP-dependent.
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 3.7. Activity of pyruvate dehydrogenase complex
PDC plays a key role in the regulation of glycolysis and
its activity largely determines the fate of the glycolytic
product pyruvate, i.e. mitochondrial oxidation or anaerobic
conversion into lactate. As such, it is tempting to speculate
that uncoupling between glycolysis and glucose oxidation
is based on changes in the regulation of PDC. The
observation that total PDC content was not affected,
whereas the active form of PDC is diminished in the
hypertrophied myocardium is in line with this notion
[67]. In addition to modulation by acetyl-CoA/CoA ratio
and other metabolites, PDC activity is controlled by
phosphorylation/dephosphorylation. Interestingly, the ex-
pression of one of the pyruvate dehydrogenase kinase
isoforms (PDK4) is induced by peroxisome proliferator-
activated receptors (PPARs: to be discussed in detail later)
[68]. The PDK4-dependent phosphorylation of PDC inhib-
its the conversion of pyruvate into acetyl-CoA. Accord-
ingly, the activation of PPAR promotes the utilization of
FA, at the same time suppressing glucose oxidation (via
PDK4!PDC). Vice versa, it is conceivable that inhibition
of PPAR activity, as has been demonstrated in the setting
of cardiac hypertrophy, stimulates glucose oxidation by
relieving the inhibition of PDC.
3.8. Impairment of fatty acid oxidation and peroxisome
proliferator-activated receptors
Sack et al. [69] were the first to report a decrease in the
expression of genes involved in mitochondrial h-oxidation
in the hypertrophied and failing myocardium. Subsequent
studies showed that the expression of a variety of genes
involved in FA uptake and metabolism is diminished in
experimental models of cardiac hypertrophy and failure
[25,49,50,70] as well as in left ventricular tissue of human
cardiac transplant recipients [71]. The finding that the
exposure of cardiac myocytes to FA elicits a co-coordinated
up-regulation of genes encoding for proteins involved in FA
uptake and metabolism [72–74] and the subsequent eluci-
dation of the role of PPARa herein [73,74] suggested that
PPARs play a pivotal role in metabolic remodelling. Col-
lectively, these data suggested that the reduction in FA
oxidation in the hypertrophic and failing heart could be
attributed to a down-regulation of the expression of genes
involved in FA transport and metabolism as a result of a
decline in PPAR activity.
The PPARa, h/y, and g isotypes form dimers with RXR
and the PPAR/RXR heterodimers are capable of binding to
the DNA consensus binding sequence (AGGTCA-
nAGGTCA), referred to as peroxisome proliferator re-
sponse element (PPRE) (for recent reviews, see Refs.
[75,76]). The expression level of the three PPAR isotypes
varies from tissue to tissue. In the intact heart all three
isotypes are present, the RNA content of PPARa and
PPARh/y being comparable and much higher than that of
PPARg [77]. The expression level of the PPAR isotypes,
however, is likely to change under various pathological
conditions. For both PPARa and RXRa, it has been shown
that their content, at the mRNA as well as protein level, is
decreased in the failing heart [70,78,79]. The reduction in
the amount of functional PPARa/RXRa complexes offers
an attractive explanation for the observed decline in the
expression of genes involved in FA metabolism under these
circumstances.
The transcriptional activity of PPAR/RXR is also mod-
ulated by a variety of co-repressor and co-activator proteins.
The biological significance of the co-activator peroxisome-
proliferator receptor-g co-activator-1 (PGC-1), which is
abundantly expressed in the cardiac muscle, has received
widespread attention. PGC-1 also serves as co-activator of
the nuclear respiratory factors (NRFs), transcription factors
that control mitochondrial biogenesis [80]. Accordingly,
PGC-1 is ideally suited to keep FA oxidation capacity and
mitochondrial biogenesis in balance. Indeed, the overex-
pression of PGC-1 in skeletal muscle both increases FA
oxidation rate and mitochondrial number [81]. Recently, it
was shown that cardiac PGC-1 expression is reduced in a rat
model of cardiac failure [82], further lending support to the
importance of this co-factor in the metabolic remodelling of
the failing heart.
In addition to PPARs several other nuclear receptors,
among which chicken ovalbumin upstream promoter tran-
scription factor (COUP-TF), are able to bind to the consen-
sus PPRE sequence. In contrast to PPARa, the binding of
COUP-TF to PPRE sequences suppresses transcriptional
activity [83]. COUP-TF is increased in the hypertrophied
heart [70], suggesting that competition between PPAR and
COUP-TF for binding to promoter sequences might be
responsible for the repression of the expression of FA-
metabolising gene products.
Finally, evidence has been provided that PPARa is
subject to phosphorylation by mitogen-activated protein
(MAP) kinases. In cardiac muscle cells, p38 MAP kinase-
dependent phosphorylation of PPARa led to an increase in
PPARa activity [84]. However, the exact effect of the MAP
kinase-dependent phosphorylation is far from clear as the
phosphorylation of PPARa via another MAP kinase, i.e. via
ERK, appeared to have opposite effects [85]. Given the fact
that the activation of MAP kinases is an integral part of the
cardiac hypertrophic response, it will be important to
delineate the functional implications of PPAR phosphoryla-
tion for transcriptional activity in the heart.
Furthermore it is important to realize that, so far, research
has been focussed exclusively on the role of PPARa in
cardiac metabolic remodelling. In view of the fact that
PPARh/y is likely to be equally important in the transcrip-
tional control of cardiac FA metabolism [86], more research
into the role of this subtype in the setting of cardiac
hypertrophy and failure is warranted. Finally, it still remains
to be established whether the PPAR-mediated down-regula-
tion of these metabolic genes represents an early or late
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 phenomenon in the sequel of events ultimately leading to
cardiac failure.
3.9. Impaired uptake of fatty acids
In addition to impaired mitochondrial FA oxidation,
alterations in the transport of FA from the extracellular
compartment to the sarcoplasm could lead to disturbances
in FA utilization as well. The cellular uptake of FA is
facilitated by membrane-associated proteins, including
FAT/CD36, fatty acid transport protein (FATP) and plasma-
lemmal fatty acid-binding protein (FABPpm) [87]. Studies
on patients carrying a mutated FAT/CD36 gene suggest that
lack of the sarcolemmal FA transporter FAT/CD36 leads to
hypertrophic cardiomyopathy [88]. Recently, it was shown
that FAT/CD36 deficiency might play an important role in
the aetiology of cardiac hypertrophy in spontaneously
hypertensive rats (SHR) [89]. These findings collectively
point towards a causal relationship between a reduced
sarcolemmal capacity to transport extracellular FA and
cardiac hypertrophy. So far, it is largely unknown if the
activity of sarcolemmal FA transport proteins is affected
during acquired hypertrophy and failure.
3.10. Loss of carnitine, the carnitine shuttle, and mitochon-
drial dysfunction
Carnitine is required for the import of activated long-
chain FA into the mitochondrion via the carnitine shuttle.
This co-factor is synthesized in the liver and taken up by the
cardiac muscle cell by the organic cation transporter
(OCT2N) primarily. In experimental and clinical studies
on cardiac hypertrophy and failure, a decline in the tissue
content of total and free carnitine has been observed
[11,22,90], which is probably related to a reduction in
carrier-mediated uptake [91]. In primary carnitine deficiency
in man and in OCT2N-deficient mice, FA oxidation is
severely disturbed, resulting in the accumulation of exces-
sive amounts of intramyocardial triacylglycerols with po-
tentially noxious effects (‘lipotoxicity’) [92]. Studies on
mitochondria isolated from hypertrophic hearts indicated,
however, that carnitine supplementation was insufficient to
restore mitochondrial FA oxidation capacity [11]. The latter
observation suggests that, although the loss of carnitine in
hypertrophic hearts may be a contributing factor, it is not the
principal factor responsible for the decline in FA oxidation
capacity.
As indicated above, the activity of CPT1, and thus the
carnitine shuttle, is inhibited by malonyl-CoA. Recently, it
was shown that the expression of malonyl-CoA decarbox-
ylase (MDC), the enzyme responsible for the degradation
of malonyl-CoA, is controlled by PPAR [93]. Hence, the
decline in PPAR activity as observed during hypertrophy
may lead to a decline in MCD, resulting in a rise in
malonyl-CoA levels and inhibition of mitochondrial FA
import.
4. Metabolic remodelling: adaptive or maladaptive?
As discussed, the reduction of FA oxidation is not fully
compensated for by an enhanced glucose oxidation, which
would implicate a reduced overall rate of ATP regeneration
in the hypertrophied and failing heart. Along with ob-
served changes in mitochondrial function, the collective
findings could be interpreted as such that the failing heart
is an energy compromised organ that suffers from a
progressive ‘burn-out syndrome’ eventually leading to
functional deterioration.
The biological relevance of the shift in substrate utiliza-
tion from FA to glucose remains largely elusive. It should be
kept in mind that, as the foetal heart is also highly dependent
on carbohydrates for energy production, the metabolic
remodelling process could be considered part of the return
to the foetal gene programme, a hallmark of cardiac hyper-
trophy. Interestingly, ventricular unloading also gives rise to
the expression of foetal genes [49], which raises the ques-
tion if metabolic remodelling during hypertrophy represents
a purposeful cardiac response, or merely a fixed reaction to
a homeostatic perturbation.
Although it is realized that there is a slight oxygen
sparing effect (12%) in terms of ATP yield per oxygen
atom invested when glucose instead of FA is oxidized,
traditionally it has been assumed that metabolic therapies
should be aimed to correct the decline in FA utilization.
However, a number of observations suggests otherwise.
ATP produced in the cytoplasm via glycolysis is used
preferentially by ion pumps, including the sarcoplasmic
reticular Ca
2+-ATPase, SERCA2 [94]. In this respect, the
increased glycolytic rate might be considered an adaptive
response attenuating the disturbances in Ca
2+-homeostasis
associated with cardiac hypertrophy. In rats with pressure-
overload-induced hypertrophy, the administration of the
PPARa ligand WY14,643, with the goal to increase FA
oxidation, appeared to have adverse rather than beneficial
effects [95]. Furthermore, the cardiac-specific overexpres-
sion of GLUT1 attenuated the development of cardiac
failure [96]. Finally, drugs (ranolazine, trimetazine) that
stimulate glucose utilization, have been shown to improve
cardiac function in models of heart failure [97]. Accord-
ingly, it is tempting to speculate that the shift towards
glucose metabolism in the hypertrophied and failing heart
is beneficial in several ways, the prize being however a
reduced overall ATP production, the adverse effects of
which might dominate in the end.
5. Concluding remarks
Cardiac failure is characterized by a spectrum of alter-
ations in cardiac energy and substrate metabolism. Although
defects in mitochondrial function in end-stage cardiac dis-
ease are apparent, it remains to be established whether these
abnormalities are causally involved in the transition of
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 compensated hypertrophy to decompensated cardiac failure.
With respect to FA metabolism, it is likely that the metabolic
disturbances can be attributed to changes in the rate of
transcription of the genes involved. In case of the enhance-
ment of glucose metabolism, the mechanism responsible is
less clear and several options need to be considered. At this
moment, the functional consequences of metabolic remod-
elling in relation to the development of heart failure still
remain elusive. Given the fact that redox state, adenine
nucleotides, oxygen, FA and glucose derivatives, all serve
important roles in signal transduction in the cardiac myo-
cyte, alterations in cardiac metabolism will inevitably mod-
ulate cardiac phenotype and function. The challenge for the
near future lies in the unravelling of the intricate relationship
between energy metabolism, signal transduction and cardiac
performance.
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